Kristel Tjandra is a freelance science writer. She was an intern at Drug Discovery News in 2022. She earned a PhD in chemistry from the University of New South Wales, Australia. Kristel was a postdoctoral scholar at Stanford University where she developed rapid diagnostics for multidrug-resistant bacteria. Her research focused on therapeutics and diagnostics for cancer and infectious diseases. When not writing, she enjoys spending time outdoors playing tennis, cycling, and swimming.
Articles by Kristel Tjandra, PhD
| 9 min read
Scientists are advancing CAR T cell therapy to improve outcomes for children with acute lymphoblastic leukemia.
| 9 min read
Researchers are developing new, portable breath analysis tools to diagnose tuberculosis and other diseases, making screenings more accessible in remote areas and beyond.
| 5 min read
Initially thought of as a DNA-damaging drug, 5-fluorouracil mainly kills cancer cells by interfering with ribosomal RNA, opening up new avenues for care.
| 9 min read
There is no vaccine against this parasitic worm infection, but rhesus macaques’ unique immune system has brought the prospect of a vaccine closer than ever.
| 4 min read
Fifteen years after a worldwide scientific ocean expedition, scientists uncovered microbe genomes that produce potential therapeutics.
| 4 min read
Researchers identified immune cell imposters that are responsible for immune evasion in pancreatic cancer.
| 4 min read
Scientists developed a gel formulation that makes swallowing medicines easier.
| 3 min read
Bacteria can stop a viral infection by an act of altruistic suicide.
| 3 min read
New data suggest that an alternative mode of action may be at play for NSAIDs.
| 3 min read
A new understanding of one enzyme’s role in assembling a key macromolecule in the bacterial cell wall takes a step toward overcoming antibiotic resistance.
| 3 min read
Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.
| 4 min read
Silicon nanoneedles loaded with ocular drugs hold potential to replace invasive injections to the eye.
